Expanded Access Protocol of Troriluzole in Patients With Spinocerebellar Ataxia (SCA) (NCT06034886) | Clinical Trial Compass
AVAILABLENot Applicable
Expanded Access Protocol of Troriluzole in Patients With Spinocerebellar Ataxia (SCA)
Plain-language summary
The purpose of this expanded access protocol is to provide access to the investigational drug troriluzole in patients with spinocerebellar ataxia (SCA).
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Key Inclusion Criteria:
* Patient has a confirmed diagnosis of Spinocerebellar Ataxia (SCA), defined as either clinical evidence supporting diagnosis OR confirmed genotypic diagnosis.
* Adequate hepatic function.
Key Exclusion Criteria:
* Patient is known to have acute or chronic liver disease that is clinically significant in the judgement of the Physician.
* Patient has a history of a clinically significant medical condition that would interfere with the patients ability to comply with the expanded access protocol or would place the patient at increased risk.